Table 2.
The clinicopathological data of patients according to the risk-stratified groups in the training cohort
| Variables | high-risk group (n = 201) | low-risk group (n = 180) | P |
|---|---|---|---|
| Age, years | 51.7 ± 11.3 | 50.8 ± 11.0 | 0.409 |
| Sex | 0.551 | ||
| Male | 173 (86.1%) | 151 (83.9%) | |
| Female | 28 (13.9%) | 29 (16.1%) | |
| BMI, Kg/m2 | 0.258 | ||
| <18.5 | 17 (8.5%) | 10 (5.5%) | |
| 18.5–25 | 129 (64.2%) | 130 (72.2%) | |
| ≥ 25 | 55 (27.4%) | 40 (22.2%) | |
| HBsAg | 0.367 | ||
| Positive | 170 (84.6%) | 158 (87.8%) | |
| Negative | 31 (15.4%) | 22 (12.2%) | |
| HBV-DNA (copies/ml) | 0.068 | ||
| <103 | 84 (41.8%) | 92 (51.1%) | |
| ≥ 103 | 117 (58.2%) | 88 (48.9%) | |
| Liver cirrhosis | 0.086 | ||
| Present | 131 (65.2%) | 132 (73.3%) | |
| Absent | 70 (34.8%) | 48 (26.7%) | |
| Child-Pugh classification | 0.738 | ||
| A | 193 (96.0%) | 174 (96.7%) | |
| B | 8 (4.0%) | 6 (3.3%) | |
| Previous abdominal surgery | 0.285 | ||
| Present | 36 (17.9%) | 25 (13.9%) | |
| Absent | 165 (82.1%) | 155 (86.1%) | |
| Comorbidities | 0.242 | ||
| Present | 43 (21.4%) | 30 (16.7%) | |
| Absent | 158 (78.6%) | 150 (83.3%) | |
| AFP, ng/mL | 0.007 | ||
| < 400 | 110 (54.7%) | 123 (68.3%) | |
| ≥ 400 | 91 (45.3%) | 57 (31.7%) | |
| CEA, ng/mL | 0.543 | ||
| Normal | 159 (79.1%) | 138 (76.7%) | |
| Abnormal | 42 (20.9%) | 42 (23.3%) | |
| CA19–9, U/ml | 0.639 | ||
| Normal | 121 (60.2%) | 112 (62.2%) | |
| Anormal | 80 (39.8%) | 68 (37.8%) | |
| TBIL, umol/L | 14 (11.1–18.1) | 14.0 (10.7–17.3) | 0.948 |
| DBIL, umol/L | 5.6 (4.2–7.0) | 5.4 (4.0–6.8) | 0.375 |
| ALT, IU/L | 38.0 (26.0–56.5) | 37.0 (27.0–56.5) | 0.880 |
| AST, IU/L | 43.0 (31.0–72.0) | 36.0 (28.0–45.8) | < 0.001 |
| Albumin, g/L | 0.483 | ||
| < 35 | 16 (8.0%) | 11 (6.1%) | |
| ≥ 35 | 185 (92.0%) | 169 (93.9%) | |
| NLR | 2.2 (1.7–3.1) | 2.2 (1.7–2.9) | 0.113 |
| PLR | 92.9 (65.1–128.3) | 83.7 (62.6–114.3) | 0.001 |
| ASA grade | 0.199 | ||
| II | 162 (80.6%) | 154 (85.6%) | |
| III | 39 (19.4%) | 26 (14.4%) | |
| Largest tumor size, cm | 7.0 (5.0–10.0) | 3.7 (2.5–5.0) | <0.001 |
| Tumor number | 0.709 | ||
| Solitary | 188 (93.5%) | 170 (94.4%) | |
| Multiple | 13 (6.5%) | 10 (5.6%) | |
| Hepatectomy | 0.245 | ||
| Anatomical | 118 (58.7%) | 95 (52.8%) | |
| Nonanatomical | 83 (41.3%) | 85 (47.2%) | |
| Hemorrhage, ml | < 0.001 | ||
| < 200 | 53 (26.4%) | 80 (44.4%) | |
| ≥ 200 | 148 (73.6%) | 100 (55.6%) | |
| Intraoperative transfusion | 0.019 | ||
| Yes | 22 (10.9%) | 8 (4.4%) | |
| No | 179 (89.1%) | 172 (95.6%) | |
| Differentiation | 0.068 | ||
| poor | 98 (48.8%) | 71 (39.4%) | |
| Well-moderate | 103 (51.2%) | 109 (60.6%) | |
| MVI | < 0.001 | ||
| Present | 87 (43.3%) | 37 (20.6%) | |
| Absent | 114 (56.7%) | 143 (79.4%) | |
| Capsule | < 0.001 | ||
| Incomplete | 137 (68.2%) | 78 (43.3%) | |
| Complete | 64 (31.8%) | 102 (56.7%) | |
| Rad-score | −0.1(−0.3 ~ 0.5) | −0.8(−1.0 ~ −0.7) | < 0.001 |
ASA American Society of Anesthesiologists, BMI Body mass index, AFP α-fetoprotein, ALT Alanine transaminase, AST Aspartate aminotransferase, NLR Neutrophil-to-lymphocyte ratio, PLR Platelet lymphocyte ratio, MVI Microvascular invasion, Rad-score Radiomics score